FAK
シグナル伝達経路
研究分野
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S2672 | PF-00562271 Besylate | <1 mg/mL | 14 mg/mL | <1 mg/mL |
| S2890 | PF-562271 | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S2013 | PF-573228 | <1 mg/mL | 26 mg/mL | <1 mg/mL |
| S2820 | TAE226 (NVP-TAE226) | <1 mg/mL | 94 mg/mL | <1 mg/mL |
| S2725 | PF-03814735 | <1 mg/mL | 0.4 mg/mL | <1 mg/mL |
| S5321 | Y15 | 56 mg/mL | 56 mg/mL | <1 mg/mL |
| S7357 | PF-562271 HCl | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S8523 | GSK2256098 | <1 mg/mL | 82 mg/mL | 82 mg/mL |
| S7653 | PND-1186 (VS-4718) | <1 mg/mL | 24 mg/mL | <1 mg/mL |
| S7644 | PF-431396 | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S7654 | Defactinib (VS-6063, PF-04554878) | <1 mg/mL | 5 mg/mL | <1 mg/mL |
- FAK阻害剤(12)
- 新FAK製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S2672 |
PF-00562271 BesylatePF-00562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1. |
|
|
| S2890 |
PF-562271PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. |
Effect of matrix stiffness on the susceptibility of primary HDFs to apoptosis induced by inhibition of mechanotransduction pathways. HDFs (primary human dermal fibroblasts) were cultured on collagen-coated polyacrylamide hydrogels that recapitulated the stiffness of normal (4 kPa) or densely fibrotic (50 kPa) skin for 24 hours and treated with or without the agents indicated for an additional 48 hours. Apoptosis was assessed by annexin V staining. Data are means ± SD from three independent experiments. P value was determined by Student’s t test.
|
|
| S2013 |
PF-573228PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β. |
FAK inhibition blunted the increased migration induced by PGC1α depletion. G361 cells were subjected to 24 h transwell migration assays in the presence of DMSO or various doses of FAK inhibitor PF-573228. Images represent three pictures captured with scale bar representing 100 μm. |
|
| S2820 |
TAE226 (NVP-TAE226)TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. |
Targeting the actin cytoskeleton overcomes resistance to HDACi in primary MM. Graphs representing the proportion of cell death induced in MM patients (n=6) treated LBH589 (5 nM), TAE226 (0.5 uM) and combination. |
|
| S2725 |
PF-03814735PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1. |
(A) Immunoblot demonstrating the expression of phospho-FAK in parental (PAR) and mesenchymal (MES) HCC827 cells following exposure to dasatinib (50nM), PF-562271 (1μM), PF-562271 (1μM) and PF-0381473 for 2 and 24 hours.
|
|
| S5321新 |
Y15Y15 is a small-molecule FAK scaffolding inhibitor that directly inhibits FAK autophosphorylation in a dose- and time-dependent manner. |
||
| S2360新 |
Solanesol (Nonaisoprenol)Solanesol is a long-chain polyisoprenoid alcohol compound with inhibitory activities toward FAK. It mainly accumulates in solanaceous crops, including tobacco, tomato, potato, eggplant, and pepper plants. |
||
| S7357 |
PF-562271 HClPF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1. |
NO production was increased in the netrin-1-over-expressing and recombinant netrin-1-treated MiaPaCa II cells. FAK inhibitor PF-562271 blocks the netrin-1-induced NO production. (*P < 0.05).
|
|
| S8523 |
GSK2256098GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM. |
||
| S7653 |
PND-1186 (VS-4718)PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1. |
(a) Percentage of apoptotic HepG2 and Huh7.5 cells after 48 h of treatment with DMSO (Vehicle), 0.5 μM or 1 μM PND 1186 measured by Annexin V and flow cytometry. Values are plotted as mean±SD (*P<0.05; **P<0.01; versus Vehicle, n =3). (b) Representative WB for p21 and caspase-3 in HepG2 and Huh7.5 cells after 48 h of treatment with DMSO (0), 0.5 μM or 1 μM PND 1186. β-tubulin is reported as a loading control (n=2). (c) Relative mRNA expression of EZH2 and NOTCH2 genes as measured by qRT-PCR in HepG2 and Huh7.5 cells after 48 h of treatment with DMSO (Vehicle), 0.5 μM or 1 μM PND 1186 (*P<0.05; **P<0.01; versus Vehicle, n =3). |
|
| S7644 |
PF-431396PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively. |
||
| S7654 |
Defactinib (VS-6063, PF-04554878)Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2. |
(C) D2.A1 cells were pretreated for 18 hours with the indicated concentration of Defactinib. (D) D2.A1 cells were pretreated for 10 minutes with indicated concentrations of Defactinib. cells were serum starved for 18 hours with or without inhibitor pretreatment and cells were subsequently stimulated with FGF2 (20ng/ml) for 30 minutes and analyzed by immunoblot for downstream phosphorylation of Erk1/2. Expression of total Erk1/2 was analyzed as a loading control.
|
